Eli Lilly's Foundayo Logs Under 4,000 Prescriptions in Second Week, Trails Rival
LLY sits 44% above its 52-week low of $623.78.
Summary
Eli Lilly's new oral obesity drug, Foundayo, recorded 3,707 prescriptions in its second week after launch, following 1,390 in its debut week. This initial uptake is significantly slower than rival Novo Nordisk's oral Wegovy, which saw 18,410 prescriptions in its second week. This news follows the official launch of Foundayo on April 10th. Analysts are interpreting this early performance negatively, leading to a pre-market decline in Lilly's shares. The market is closely watching Foundayo's rollout as a critical test of Lilly's competitive position in the lucrative obesity drug market, and these early figures suggest a challenging ramp-up against an entrenched competitor.
At the time of this announcement, LLY was trading at $899.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $867B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.